[Conjugates of 2',3'-didehydro-3'-deoxythymidine with thymogen. Synthesis and anti-HIV activity]. 1999

V V Riakhovskiĭ, and S I Malekin, and V M Nosova, and A V Kisin, and Iu L Krugliak, and V K Kurochkin
State Research Institute of Organic Chemistry and Technology, Moscow, Russia.

An effective synthesis of thymogen was developed. Conjugates of 2',3'-didehydro-3'-deoxythymidine (nucleoside d4T) with thymogen were prepared in which the nucleoside hydroxyl group was linked to the thymogen carboxyl group of either tryprophan or glutamic acid residues. It was shown that the anti-HIV activity of the d4T-thymogene conjugate with the tryptophan linkage was comparable to that of d4T, whereas its cytotoxicity was nil. The d4T-tryptophan conjugate also displayed high anti-HIV activity.

UI MeSH Term Description Entries
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D004151 Dipeptides Peptides composed of two amino acid units. Dipeptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D018119 Stavudine A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. 2',3'-Didehydro-3'-deoxythymidine,D4T,2',3'-Didehydro-2',3'-dideoxythmidine,BMY-27857,Stavudine, Monosodium Salt,Zerit,2',3' Didehydro 3' deoxythymidine,BMY 27857,BMY27857
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

V V Riakhovskiĭ, and S I Malekin, and V M Nosova, and A V Kisin, and Iu L Krugliak, and V K Kurochkin
January 2004, Nucleosides, nucleotides & nucleic acids,
V V Riakhovskiĭ, and S I Malekin, and V M Nosova, and A V Kisin, and Iu L Krugliak, and V K Kurochkin
January 1990, Drug metabolism and disposition: the biological fate of chemicals,
V V Riakhovskiĭ, and S I Malekin, and V M Nosova, and A V Kisin, and Iu L Krugliak, and V K Kurochkin
July 1998, Bioorganic & medicinal chemistry letters,
V V Riakhovskiĭ, and S I Malekin, and V M Nosova, and A V Kisin, and Iu L Krugliak, and V K Kurochkin
June 1995, Antiviral research,
V V Riakhovskiĭ, and S I Malekin, and V M Nosova, and A V Kisin, and Iu L Krugliak, and V K Kurochkin
December 1993, Journal of pharmaceutical sciences,
V V Riakhovskiĭ, and S I Malekin, and V M Nosova, and A V Kisin, and Iu L Krugliak, and V K Kurochkin
March 1994, Journal of pharmaceutical sciences,
V V Riakhovskiĭ, and S I Malekin, and V M Nosova, and A V Kisin, and Iu L Krugliak, and V K Kurochkin
January 2013, Bioorganicheskaia khimiia,
V V Riakhovskiĭ, and S I Malekin, and V M Nosova, and A V Kisin, and Iu L Krugliak, and V K Kurochkin
January 1990, Journal of medicinal chemistry,
V V Riakhovskiĭ, and S I Malekin, and V M Nosova, and A V Kisin, and Iu L Krugliak, and V K Kurochkin
January 2002, Organic letters,
V V Riakhovskiĭ, and S I Malekin, and V M Nosova, and A V Kisin, and Iu L Krugliak, and V K Kurochkin
January 1999, Drug metabolism and disposition: the biological fate of chemicals,
Copied contents to your clipboard!